lvi breast cancer

Release time ：Dec-22,2024

Breast cancer is a prevalent malignant neoplasm, characterized pathologically by lymphovascular invasion (LVI). The presence of LVI suggests the potential for cancer cells to enter the circulatory system via lymphatic or blood vessels, thereby increasing the risk of distant metastasis. Consequently, comprehending LVI is crucial for the prognosis and therapeutic strategies of patients with breast cancer.

The diagnosis of LVI predominantly depends on pathological examination. Pathologists meticulously scrutinize excised breast tissue for evidence of cancer cells infiltrating lymphatic or blood vessels. A positive LVI result typically signals a heightened risk of recurrence and metastasis for the patient, influencing treatment decisions.

Patients with LVI-positive breast cancer may necessitate more aggressive therapeutic interventions, including adjuvant chemotherapy, radiation therapy, or endocrine therapy. Additionally, for those with HER2-positive status, targeted therapy might be indicated. These treatments aim to mitigate the risks of cancer recurrence and metastasis, thereby enhancing patient survival rates.

Regular follow-up and monitoring are essential for breast cancer patients. Even after completing all treatments, it is imperative for patients to vigilantly monitor their health, promptly identifying any anomalies and seeking medical care. Maintaining a healthy lifestyle, such as a balanced diet, regular exercise, and abstaining from smoking and limiting alcohol consumption, can also contribute to reducing the risk of cancer recurrence. In conclusion, addressing breast cancer, a disease that significantly threatens women's health, requires a multifaceted approach to treatment and vigilant monitoring of disease progression to optimize therapeutic outcomes.